LU81797A1 - Combinations antivirales - Google Patents

Combinations antivirales Download PDF

Info

Publication number: LU81797A1
Authority: LU; Luxembourg
Prior art keywords: ethyl; combination; quinoxaline; dihydro; mixture
Prior art date: 1979-06-18

Application number

LU81797A

Other languages

English (en)

French (fr)

Inventor

D Delong

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-06-18

Filing date

1979-10-18

Publication date

1980-01-25

1979-10-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1980-01-25 Publication of LU81797A1 publication Critical patent/LU81797A1/fr

Links

230000000840 anti-viral effect Effects 0.000 title claims description 9
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 27
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 10
150000001412 amines Chemical class 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
241000712461 unidentified influenza virus Species 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 6
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 6
JEPPYVOSGKWVSJ-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(N)CC1C2 JEPPYVOSGKWVSJ-UHFFFAOYSA-N 0.000 claims description 6
HSOHBWMXECKEKV-UHFFFAOYSA-N cyclooctanamine Chemical compound NC1CCCCCCC1 HSOHBWMXECKEKV-UHFFFAOYSA-N 0.000 claims description 6
239000003443 antiviral agent Substances 0.000 claims description 5
208000015181 infectious disease Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 3
ZAFFWAGKFUGBKJ-UHFFFAOYSA-N ethyl 6,7-dibromo-3-oxo-4h-quinoxaline-2-carboxylate Chemical compound BrC1=C(Br)C=C2NC(=O)C(C(=O)OCC)=NC2=C1 ZAFFWAGKFUGBKJ-UHFFFAOYSA-N 0.000 claims description 3
UPUZGXILYFKSGE-UHFFFAOYSA-N quinoxaline-2-carboxylic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CN=C21 UPUZGXILYFKSGE-UHFFFAOYSA-N 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
239000000203 mixture Substances 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 14
238000000034 method Methods 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000003814 drug Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
238000010992 reflux Methods 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 5
150000002148 esters Chemical group 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
-1 quinoxalinecarboxylic acid ester Chemical class 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DBKKFIIYQGGHJO-UHFFFAOYSA-N diethyl 2-oxopropanedioate Chemical compound CCOC(=O)C(=O)C(=O)OCC DBKKFIIYQGGHJO-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
206010022000 influenza Diseases 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
MWMFMCTUGUZSJJ-UHFFFAOYSA-N 3-methyladamantan-1-amine Chemical compound C1C(C2)CC3CC1(C)CC2(N)C3 MWMFMCTUGUZSJJ-UHFFFAOYSA-N 0.000 description 2
QIDSVLUIWDDFKL-UHFFFAOYSA-N 4,5-dibromo-2-nitroaniline Chemical compound NC1=CC(Br)=C(Br)C=C1[N+]([O-])=O QIDSVLUIWDDFKL-UHFFFAOYSA-N 0.000 description 2
TTXGKCVKGXHPRI-UHFFFAOYSA-N 4,5-dibromobenzene-1,2-diamine Chemical compound NC1=CC(Br)=C(Br)C=C1N TTXGKCVKGXHPRI-UHFFFAOYSA-N 0.000 description 2
XXIFMWKGKJWFOH-UHFFFAOYSA-N 4-bromo-5-chloro-2-nitroaniline Chemical compound NC1=CC(Cl)=C(Br)C=C1[N+]([O-])=O XXIFMWKGKJWFOH-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
229960003805 amantadine Drugs 0.000 description 2
WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
HYJMCMPIILIFMD-UHFFFAOYSA-N ethyl 3-(4-bromo-5-chloro-2-nitroanilino)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NC1=CC(Cl)=C(Br)C=C1[N+]([O-])=O HYJMCMPIILIFMD-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
JNTOKFNBDFMTIV-UHFFFAOYSA-N propyl nitrate Chemical compound CCCO[N+]([O-])=O JNTOKFNBDFMTIV-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
IWFHBRFJOHTIPU-UHFFFAOYSA-N 4,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(Cl)C=C1N IWFHBRFJOHTIPU-UHFFFAOYSA-N 0.000 description 1
LWFDMVFVKWWYFN-UHFFFAOYSA-N 6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylicacid Chemical compound ClC1=C(Cl)C=C2NC(=O)C(C(=O)O)=NC2=C1 LWFDMVFVKWWYFN-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
HKNSIVFWRXBWCK-UHFFFAOYSA-N [N].NC1=CC=CC=C1 Chemical compound [N].NC1=CC=CC=C1 HKNSIVFWRXBWCK-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
VVOCYQDSDXLBEA-UHFFFAOYSA-N dimethyl 2-oxopropanedioate Chemical compound COC(=O)C(=O)C(=O)OC VVOCYQDSDXLBEA-UHFFFAOYSA-N 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
YLQARHIFEKQCLD-UHFFFAOYSA-N ethyl 6,7-dichloro-3-oxo-2,4-dihydro-1h-quinoxaline-2-carboxylate Chemical compound ClC1=C(Cl)C=C2NC(=O)C(C(=O)OCC)NC2=C1 YLQARHIFEKQCLD-UHFFFAOYSA-N 0.000 description 1
HVUUAJYWVAZYAU-UHFFFAOYSA-N ethyl 6,7-dichloro-3-oxo-4h-quinoxaline-2-carboxylate Chemical compound ClC1=C(Cl)C=C2NC(=O)C(C(=O)OCC)=NC2=C1 HVUUAJYWVAZYAU-UHFFFAOYSA-N 0.000 description 1
MXRQCKOJQVLMPR-UHFFFAOYSA-N ethyl 7-bromo-6-chloro-1-oxido-3-oxo-2h-quinoxalin-1-ium-2-carboxylate Chemical compound C1=C(Cl)C(Br)=CC2=[N+]([O-])C(C(=O)OCC)C(=O)N=C21 MXRQCKOJQVLMPR-UHFFFAOYSA-N 0.000 description 1
VHHFLIVSBISZQJ-UHFFFAOYSA-N ethyl 7-bromo-6-chloro-3-oxo-4h-quinoxaline-2-carboxylate Chemical compound BrC1=C(Cl)C=C2NC(=O)C(C(=O)OCC)=NC2=C1 VHHFLIVSBISZQJ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
CQZVBBDKVGDSMQ-UHFFFAOYSA-N methyl 6,7-dichloro-3-oxo-4h-quinoxaline-2-carboxylate Chemical compound ClC1=C(Cl)C=C2NC(=O)C(C(=O)OC)=NC2=C1 CQZVBBDKVGDSMQ-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
150000004987 o-phenylenediamines Chemical class 0.000 description 1
XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
150000003252 quinoxalines Chemical class 0.000 description 1
229960000888 rimantadine Drugs 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU81797A 1979-06-18 1979-10-18 Combinations antivirales LU81797A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/049,671 US4210647A (en)	1979-06-18	1979-06-18	Antiviral combinations
US4967179		1979-06-18

Publications (1)

Publication Number	Publication Date
LU81797A1 true LU81797A1 (fr)	1980-01-25

Family

ID=21961053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU81797A LU81797A1 (fr)	1979-06-18	1979-10-18	Combinations antivirales

Country Status (12)

Country	Link
US (1)	US4210647A (ja)
EP (1)	EP0020836A1 (ja)
JP (1)	JPS565416A (ja)
AU (1)	AU5197679A (ja)
BE (1)	BE879473A (ja)
CA (1)	CA1121268A (ja)
FR (1)	FR2459045A1 (ja)
GB (1)	GB2050826A (ja)
IT (1)	IT1193508B (ja)
LU (1)	LU81797A1 (ja)
PH (1)	PH15454A (ja)
ZA (1)	ZA795493B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE33080E (en) *	1981-08-31	1989-10-03	Exxon Research And Engineering Company	Adamantane catalyzed paraffin isomerization
JPS63503070A (ja) *	1986-03-31	1988-11-10	ローヌープーラン・ネーデルランド・ベー・ベー	マロン酸誘導体化合物の作物収穫量を増大させるための使用
HUP0002853A3 (en) *	1997-09-01	2001-12-28	Kyorin Seiyaku Kk	6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them
DE102006056778A1 (de) *	2006-12-01	2008-06-05	Huhtamaki Ronsberg, Zweigniederlassung Der Huhtamaki Deutschland Gmbh & Co. Kg	Verfahren zum Herstellen eines mehrschichtigen Laminats
JP6321673B2 (ja) *	2012-12-20	2018-05-09	ルゥチーン−ビン	放射線と組み合わせて使用するための放射線増感剤化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB668412A (en) *	1949-07-20	1952-03-19	Justus Kenneth Landquist	New quinoxaline derivatives
DE1793190A1 (de) *	1963-04-15	1971-12-16	Du Pont	Verfahren zur Herstellung von 1-Amino-Adamantanen
US3355355A (en) *	1965-02-05	1967-11-28	Smith Kline French Lab	Antiviral cycloalkylamine compositions and method
US3582315A (en) *	1968-03-22	1971-06-01	Lilly Co Eli	Methods and compositions for inhibiting plant growth
GB1408675A (en)	1973-03-16	1975-10-01	Allen & Hanburys Ltd	Amides derived from quinoxaline
US4181724A (en) *	1978-09-11	1980-01-01	The Upjohn Company	Quinoxalinone compounds useful for expanding the lumina or air passages in mammals

1979
- 1979-06-18 US US06/049,671 patent/US4210647A/en not_active Expired - Lifetime
- 1979-10-15 PH PH23168A patent/PH15454A/en unknown
- 1979-10-15 ZA ZA00795493A patent/ZA795493B/xx unknown
- 1979-10-16 GB GB7935845A patent/GB2050826A/en not_active Withdrawn
- 1979-10-16 EP EP79302230A patent/EP0020836A1/en not_active Withdrawn
- 1979-10-18 BE BE1/9574A patent/BE879473A/fr unknown
- 1979-10-18 FR FR7925931A patent/FR2459045A1/fr not_active Withdrawn
- 1979-10-18 CA CA000337951A patent/CA1121268A/en not_active Expired
- 1979-10-18 LU LU81797A patent/LU81797A1/fr unknown
- 1979-10-19 AU AU51976/79A patent/AU5197679A/en not_active Abandoned
- 1979-10-19 JP JP13583379A patent/JPS565416A/ja active Pending
- 1979-10-19 IT IT26663/79A patent/IT1193508B/it active

Also Published As

Publication number	Publication date
AU5197679A (en)	1981-01-08
IT1193508B (it)	1988-07-08
EP0020836A1 (en)	1981-01-07
BE879473A (fr)	1980-04-18
CA1121268A (en)	1982-04-06
GB2050826A (en)	1981-01-14
IT7926663A0 (it)	1979-10-19
JPS565416A (en)	1981-01-20
ZA795493B (en)	1981-05-27
US4210647A (en)	1980-07-01
FR2459045A1 (fr)	1981-01-09
PH15454A (en)	1983-01-18

Publication	Publication Date	Title
CH644105A5 (fr)	1984-07-13	Acides et esters 4-amino-3-quinoleinecarboxyliques, utiles notamment comme agent antisecretoires et anti-ulcere.
CH620907A5 (en)	1980-12-31	Process for the preparation of antimicrobial bispyridinium derivatives
FR2534257A1 (fr)	1984-04-13	Nouveaux derives de la 6-amino 7-hydroxy 4,5,6,7-tetrahydro-imidazo/4,5,1-j-k/ /1/ benzazepin-2(1h)-one, leurs sels, application a titre de medicaments, compositions les renfermant et un intermediaire
FR2496102A1 (fr)	1982-06-18	Benzopyranes 7-substitues, leur preparation et leur application en tant que medicaments
KR102628396B1 (ko)	2024-01-24	샤프롱-매개 자가포식 조절제로서 유용한 화합물
LU81798A1 (fr)	1980-04-21	Composition pharmaceutique contenant des 3,4-dihydro-3-oxo-2-quinoxalines
CN108069942A (zh)	2018-05-25	苯酞吡唑酮类偶联物、其制备方法和用途
FR2467848A1 (fr)	1981-04-30	Sels d'acides 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxalinecarboxyliques et d'amines steriquement encombrees, leur preparation et leur utilisation therapeutique
FR2476071A1 (fr)	1981-08-21	Nouveaux acides 2-amino-3-(a-hydroxybenzyl)-phenylacetiques et leurs esters et amides, utiles notamment comme agents anti-inflammatoires, et compositions pharmaceutiques les contenant
FR2459045A1 (fr)	1981-01-09	Combinaisons antivirales comprenant une quinoxaline et une amine steriquement encombree
EP0117196A1 (fr)	1984-08-29	Nouveaux dérivés de bétaines n-iminopyridinium, leur préparation et leur application en tant que médicaments
EP1461319B1 (fr)	2009-04-29	Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives
CH642378A5 (fr)	1984-04-13	Nouveau derive du paracetamol, son procede de preparation et son utilisation en therapeutique.
LU83713A1 (fr)	1982-05-07	Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant
US9586925B2 (en)	2017-03-07	1-(dimethylamino)ethyl-substituted 6H-benzo[C]chromen-6-ones against senile dementia
EP0347305B1 (fr)	1993-05-12	[(Aryl-4-pipérazinyl-1)-2 éthoxy]-3 p-cymène, les dérivés ortho, méta, para monosubstitués ou disubstitués sur le noyau phényle dudit produit, le procédé de préparation desdits dérivés, et les médicaments contenant lesdits composés comme principe actif
EP0005422B1 (fr)	1982-10-27	Dérivés d'acides oméga-dialkylalkanoiques, leurs procédés de préparation ainsi que leur utilisation en thérapeutique
FR2478094A1 (fr)	1981-09-18	Derives de cinnamylmoranoline a substitution ammonio, a activite d'inhibition de l'augmentation de niveau de sucre dans le sang
OA13294A (fr)	2007-04-13	Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques.
US4271162A (en)	1981-06-02	Antiviral combinations
EP0022737B1 (fr)	1982-06-09	Imines dérivées de l'amino-5 benzodioxole-1,3 utiles comme médicaments et leur préparation
CH648295A5 (fr)	1985-03-15	Acides 2-amino-3-(alkylthiobenzyl)-phenylacetiques et leurs derives.
US4289773A (en)	1981-09-15	Antiviral combinations
US4355030A (en)	1982-10-19	Antiviral combinations
FR2601950A1 (fr)	1988-01-29	N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant